RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx is a clinical-stage biopharmaceutical company with a promising outlook due to strong commercialization efforts of its FDA-cleared medical device, a large market potential for its pancreatic cancer therapy, a new CFO with experience in publicly traded companies, positive interim analysis for its Phase III trial, and a strong pipeline of precision oncology therapies. We also note the company's strong progress in both clinical drug development and commercialization efforts, which is expected to result in significant revenue growth in 2026/27. Despite the risks inherent in the biotech industry, we believe the company's current valuation presents an attractive investment opportunity with potential for significant upside.

RenovoRx is a clinical-stage biopharmaceutical company with a strong balance sheet, having raised $10 million in Q1 and appointing a new CFO in February 2026. However, its current valuation may be overstated considering its lack of revenues and large transaction costs, warrant liability. Additionally, its Phase III trial for TIGeR-PaC showed positive results in the 1st interim analysis, but it may be too early to fully assess the potential for a positive outcome.